Advertisement

Topics

Latest "Guanfacine extended release tablets Placebo comparator Attention Deficit" News Stories

17:19 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Guanfacine extended release tablets Placebo comparator Attention Deficit" found in our extensive news archives from over 250 global news sources.

More Information about Guanfacine extended release tablets Placebo comparator Attention Deficit on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Guanfacine extended release tablets Placebo comparator Attention Deficit for you to read. Along with our medical data and news we also list Guanfacine extended release tablets Placebo comparator Attention Deficit Clinical Trials, which are updated daily. BioPortfolio also has a large database of Guanfacine extended release tablets Placebo comparator Attention Deficit Companies for you to search.

Showing "Guanfacine extended release tablets Placebo comparator Attention Deficit" News Articles 1–25 of 9,400+

Sunday 17th February 2019

Global Morphine Sulfate Market Research Report 20122024 [Report Updated: 01011970] Prices from USD $1800

The global Morphine Sulfate market will reach Volume Million USD in 2017 with CAGR xx% 20192023. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.Based on products type, the report describes major pr...


Saturday 16th February 2019

Interim data from the Merck KGaA, Darmstadt, Germany and Pfizer Alliance’s PhIII study in advanced RCC published in @NEJM. Additional data in advanced RCC presented at #GU19 Learn more here: https://www.pfizer.com/news/press-release/press-release-deta

Interim data from the Merck KGaA, Darmstadt, Germany and Pfizer Alliance’s PhIII study in advanced RCC published in @NEJM. Additional data in advanced RCC presented at #GU19 Learn more here: https://www.pfizer.com/news/press-rel

#Exercise Triggers Fat to Release #Protein that Improves Glucose Tolerance: http://ow.ly/eEvh30nFLIw pic.twitter.com/zf62CPcdfH

#Exercise Triggers Fat to Release #Protein that Improves Glucose Tolerance: http://ow.ly/eEvh30nFLIw  pic.twitter.com/zf62CPcdfH


$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-ASCO-Genitourinary-Cancer-Symposium.html …

AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Di...

News digest – HPV stigma, ultra-processed foods, ‘simple’ cancer blood test and why measles isn’t a cancer cure

Science blog Stigma around HPV infection causes concern Misunderstanding and perceived stigma around the human papillomavirus (HPV) infection is concerningly high and could put women off cervical screening, reports the Independent and others. The results

Friday 15th February 2019

Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antib...

$REGN U.S. and EU Patent Office Decisions Invalidate $AMGN Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor https://investor.regeneron.com/news-releases/news-release-details/us-and-eu-patent-office-decisions-invalidate-amgen-subsidiar

$REGN U.S. and EU Patent Office Decisions Invalidate $AMGN Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor https://investor.regeneron.com/news-releases/news-release-details/us-and-eu-patent-office-decisions-invalidate-amgen-subsidiary/ …

Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019

Press release Malmö, February 15, 2019 Acarix adapts pathway for German reimbursement - Submission of new dossier by the end of February 2019 Acarix AB (publ) (ACARIX: FN Stockholm) today announced it will file for German reimbursement directly with the Federal Joint Committee (G-BA) for its CADScorSystem®. Previously, Acarix was aiming for full reimbursement in Germany by the end of 2...

Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3

Alzheimer's disease is characterized not only by extracellular amyloid plaques and neurofibrillary tangles, but also by microglia-mediated neuroinflammation. Recently, autophagy has been linked to the regulation of the inflammatory response. Thus, we investigated how an impairment of autophagy mediated by BECN1/Beclin1 reduction, as described in Alzheimer's disease patients, would influence cytoki...

I've been a Nektar bull and still am, but have to say market expectations before they release data like this are too unrealistic. If it was going to be all shooting stars, Bristol wouldn't be buying Celgene right now.

I've been a Nektar bull and still am, but have to say market expectations before they release data like this are too unrealistic. If it was going to be all shooting stars, Bristol wouldn't be buying Celgene right now.

Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders

                                                                  Amsterdam, The Netherlands, 15 February 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraor...

Six Ways to a Healthy Heart According to Mache Seibel, MD

According to American Heart Association’s 2018 statistics, cardiovascular disease accounts for nearly 836,546 deaths in the U.S. That’s about one of every three deaths, and about 92.1 million American adults are living with some form of cardiovascular disease or the after-effects of stroke.

Vivacelle Bio, Inc. Receives FDA Clearance to Enroll Patients into its Phase IIa Clinical Trial of VBI-1 for Severe Blood Loss and/or Raising Blood Pressure in Hypovolemic Subjects

Vivacelle Bio, Inc. today announces that the US. Food and Drug Administration (FDA) has granted it an Investigational New Drug (IND) clearance to proceed with its phase IIa clinical trial of the safety and efficacy of VBI-1. VBI-1 is a paradigm-changing cardiovascular support fluid that is designed for the treatment of patients with emergently life-threate...

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

Lundbeck and Otsuka's #bipolar treatment fails Phase 3 trials due to unexpected effect of #placebo http://bit.ly/2GQdaNl  #pharma #mentalhealthpic.twitter.com/4wEnJM3uu0

Lundbeck and Otsuka's #bipolar treatment fails Phase 3 trials due to unexpected effect of #placebo http://bit.ly/2GQdaNl  #pharma #mentalhealth pic.twitter.com/4wEnJM3uu0

Hoth Therapeutics Announces Pricing of Initial Public Offering and Trading on the Nasdaq

Hoth Therapeutics (NASDAQ:HOTH) has announced the pricing of its initial public offering of 1,250,000 shares of its common stock at an initial offering price to the public of $5.60 per share. As quoted in the press release:  All shares of common stock are being offered by Hoth. In addition, Hoth has granted the underwriters a 30-day option … Continued The post Hoth Therapeutics Announces ...

LivaNova Recognizes Final Decision from the U.S. Centers for Medicare & Medicaid Services Regarding National Coverage Determination for VNS Therapy for Treatment-Resistant Depression

Company plans to submit clinical study protocol for CMS consideration LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today recognized that the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its National Coverage Determination (NCD) for the LivaNova Vagus Nerve Stimulation Therapy® (VNS Therapy) System for T...

Cyient Recognized as a "Major Contender" in Everest Group's PEAK Matrix(TM): Medical Device Engineering Services Assessment 2019

~The recognition further strengthens Cyient's position as a leading global medical technology and healthcare solutions provider HYDERABAD, India, Feb. 15, 2019 /PRNewswire/ -- Cyient, a global provider of engineering, manufacturing, geospatial, networks, digital, and operations management solutions to global industry leaders, has been p...

CORRECTING and REPLACING Zebra Medical Vision is Granted Three Israeli Government Grants to Deploy Medical Imaging AI at Scale

Zebra Medical Vision announces it’s the recipient of three grants from the Israeli innovation authority to provide AI analysis at Ichilov Hospital, and through Integrated health providers Maccabi and Clalit. Seventh paragraph of release dated February 14, 2019, quote should read: "... to advance the health of its members. Clalit is working ...

Triple Ring Technologies Executive Wins International Innovation Award

Triple Ring Technologies, a leading research and development firm that partners with its clients to develop innovative products and to launch new businesses, announces today that their Vice President of Projects, Christina Sejr Pedersen, recently

Bayer’s Investigational Darolutamide Plus ADT Significantly Extends Metastasis-Free Survival in Phase 3 Study of Non-Metastatic Castration-Resistant Prostate Cancer

WHIPPANY, N.J., Feb. 14, 2019 /PRNewswire/ — Results from the pivotal Phase III ARAMIS trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a statistically significant improvement in metastasis-free survival (MFS) with the investigational drug darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT (HR=0.41, 95% C...

Landings of Huber Heights Assisted Living and Memory Care Proudly Acknowledges Executive Director Lori Grote

Landings of Huber Heights, a Meridian Senior Living Community, is proud to recognize the contribution of Lori Grote as their Executive Director. HUBER HEIGHTS, Ohio (PRWEB) February 15, 2019 Landings of Huber Heights, a Meridian Senior Living Community, is proud to recognize the contribution of Lori Grote as their Executive Director. Landings of Huber Heights joined the Meridian Senior Living por...

New BitterWorld App Offers Platform For Venting

Patrick Mimran, the French multimedia artist best known for The Billboard Project, has unveiled a new app designed to help users express their bitter life experiences. The app, BitterWorld, was designed to help users relieve their frustration from the disappointments associated with mediocre products, services, experiences, and relationships. This pr...

First of Twelve New Aspen Dental Practices in North Carolina Opens to Make Access to Care Easier in the Tar Heel State

The new Aspen Dental office at 679 West Fleming Drive expanded dental care access in the Morganton community after opening on Thurs., Feb. 14. The office is located in Burke County – which has be


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks